GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Shares Outstanding (Diluted Average)

Starton Therapeutics (Starton Therapeutics) Shares Outstanding (Diluted Average) : 30.36 Mil (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Starton Therapeutics's average diluted shares outstanding for the quarter that ended in Jun. 2023 was 30.36 Mil.


Starton Therapeutics Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Starton Therapeutics's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics Shares Outstanding (Diluted Average) Chart

Starton Therapeutics Annual Data
Trend Mar21 Mar22 Mar23
Shares Outstanding (Diluted Average)
30.36 30.36 30.36

Starton Therapeutics Quarterly Data
Mar21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial 30.36 30.36 30.36 30.36 30.36

Starton Therapeutics Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Starton Therapeutics  (NAS:STA) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Starton Therapeutics Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Starton Therapeutics (Starton Therapeutics) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
215 College Road, Suite No.300, Paramus, NJ, USA, 07652
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines